Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (151-160 of 197) with videos related to

Pageof 20
Sort By:
Science (New York, N.Y.)|October 18, 2014
Detection of T cell responses to a ubiquitous cellular protein in autoimmune diseaseYoshinaga Ito, Motomu Hashimoto, Keiji Hirota, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2005
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerEiichi Sato, Sara H Olson, Jiyoung Ahn, et al.
BMJ Open|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)Yukinori Ozaki, Shohei Koyama, Satoshi Morita, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2017
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLCTomohira Takeoka, Hirotsugu Nagase, Koji Kurose, et al.
Liver Cancer|May 7, 2026
Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic ProfilingTomoko Aoki, Masatoshi Kudo, Satoshi Ogiso, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironmentShusuke Kawashima, Takashi Inozume, Masahito Kawazu, et al.
Haematologica|April 14, 2022
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphomaNorio Tanaka, Seiichi Mori, Kazuma Kiyotani, et al.
Esophagus : Official Journal of the Japan Esophageal Society|February 7, 2023
Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Ryosuke Kumanishi, Takatsugu Ogata, et al.
Nature Medicine|April 26, 2016
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancersTakuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Pageof 20

Showing results (151-160 of 197) with videos related to

Sort By:
Pageof 20
Science (New York, N.Y.)|October 18, 2014
Detection of T cell responses to a ubiquitous cellular protein in autoimmune diseaseYoshinaga Ito, Motomu Hashimoto, Keiji Hirota, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2005
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerEiichi Sato, Sara H Olson, Jiyoung Ahn, et al.
BMJ Open|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)Yukinori Ozaki, Shohei Koyama, Satoshi Morita, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2017
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLCTomohira Takeoka, Hirotsugu Nagase, Koji Kurose, et al.
Liver Cancer|May 7, 2026
Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic ProfilingTomoko Aoki, Masatoshi Kudo, Satoshi Ogiso, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironmentShusuke Kawashima, Takashi Inozume, Masahito Kawazu, et al.
Haematologica|April 14, 2022
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphomaNorio Tanaka, Seiichi Mori, Kazuma Kiyotani, et al.
Esophagus : Official Journal of the Japan Esophageal Society|February 7, 2023
Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Ryosuke Kumanishi, Takatsugu Ogata, et al.
Nature Medicine|April 26, 2016
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancersTakuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Pageof 20